Pain Related Quality of Life in Neurofibromatosis Type 1: A Narrative Review

被引:1
作者
Stech, Karina [1 ]
Habibi, Behnum [2 ]
机构
[1] Temple Univ, Lewis Katz Sch Med, Philadelphia, PA 19122 USA
[2] Temple Univ Hosp & Med Sch, Dept Phys Med & Rehabil, Philadelphia, PA USA
关键词
Neurofibroma; Chronic pain; Pain Interference; MEK Inhibitor; Mind-Body Intervention; SENSITIVE SENSORY NEURONS; PLEXIFORM NEUROFIBROMAS; CHILDREN; EXCITABILITY; IMPAIRMENT; TRIALS; ADULTS; IMPACT; YOUTH; NF1;
D O I
10.1007/s11916-024-01283-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose of Review: The purpose of this narrative review is to summarize pain symptomatology and mechanisms in neurofibromatosis type 1 (NF1), discuss the pain related quality of life impacts of NF1, and discuss the literature exploring interventions to improve quality of life.Recent Findings: Chronic pain in NF1 is described as headache and non-headache pain. The literature describes mechanisms contributing to neuronal hyperexcitability in the setting of reduced neurofibromin as key contributors to pain in NF1. Pain in NF1 negatively impacts quality of life with pain interference, depression, anxiety, and cognitive functioning acting as important mediators. Mitogen-activated protein kinase (MEK) inhibitors are pharmacologic agents that interfere with pain mechanisms. Mind-body interventions improve coping skills to improve quality of life.SummaryChronic pain in NF1 is heterogeneous with negative impacts on quality of life. New developments in pharmacological and non-pharmacological interventions offer promising approaches to pain management and quality of life improvement. Additional research is necessary to validate the use of MEK inhibitors and mind-body interventions in the treatment of NF1.
引用
收藏
页码:1177 / 1183
页数:7
相关论文
共 48 条
  • [1] Lovastatin as Treatment for Neurocognitive Deficits Type 1: Phase I Study
    Acosta, Maria T.
    Kardel, Peter G.
    Walsh, Karin S.
    Rosenbaum, Kenneth N.
    Gioia, Gerard A.
    Packer, Roger J.
    [J]. PEDIATRIC NEUROLOGY, 2011, 45 (04) : 241 - 245
  • [2] Epidemiology and Outcomes of Neurofibromatosis Type 1 (NF-1): Multicenter Tertiary Experience
    Almuqbil, Mohammed
    Alshaikh, Fatimah Yaseen
    Altwaijri, Waleed
    Baarmah, Duaa
    Hommady, Raid Harb
    Alshaikh, Maryam Yaseen
    Alammari, Fares
    Alhussain, Meshal
    Almotawa, Reem
    Alqarni, Faris
    Kashgari, Amna
    Alkhodair, Rayan
    Alkhater, Jumanah N.
    Alkhater, Lujeen Nasser
    Alharthi, Sawsan A.
    Alsadi, Mada Abdulkarim
    AlRumayyan, Ahmed
    [J]. JOURNAL OF MULTIDISCIPLINARY HEALTHCARE, 2024, 17 : 1303 - 1314
  • [3] A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas
    Anderson, Mary Kate
    Johnson, Meredith
    Thornburg, Lauren
    Halford, Zachery
    [J]. ANNALS OF PHARMACOTHERAPY, 2022, 56 (06) : 716 - 726
  • [4] Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas
    Armstrong, Amy E.
    Belzberg, Allan J.
    Crawford, John R.
    Hirbe, Angela C.
    Wang, Zhihong J.
    [J]. BMC CANCER, 2023, 23 (01)
  • [5] Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment
    Bellampalli, Shreya S.
    Khanna, Rajesh
    [J]. PAIN, 2019, 160 (05) : 1007 - 1018
  • [6] Bicudo NP, 2024, BRASILEIROS DERMATOL, DOI [10.1016/j.abd2023.08.011Thisarticlediscussesfactorscontributingtodecreasedqualityoflifeinneurofibromatosistype, DOI 10.1016/J.ABD2023.08.011THISARTICLEDISCUSSESFACTORSCONTRIBUTINGTODECREASEDQUALITYOFLIFEINNEUROFIBROMATOSISTYPE]
  • [7] Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management
    Borgia, Paola
    Piccolo, Gianluca
    Santangelo, Andrea
    Chelleri, Cristina
    Viglizzo, Gianmaria
    Occella, Corrado
    Minetti, Carlo
    Striano, Pasquale
    Diana, Maria Cristina
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (06)
  • [8] Understanding chronic pain in Neurofibromatosis Type 1 using the Neurofibromatosis Pain Module (NFPM)
    Buono, Frank D.
    Larkin, Kaitlyn
    Zempsky, William T.
    Grau, Lauretta E.
    Martin, Staci
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2024, 194 (06)
  • [9] Pain symptomology, functional impact, and treatment of people with Neurofibromatosis type 1
    Buono, Frank D.
    Grau, Lauretta E.
    Sprong, Matthew E.
    Morford, Kenneth L.
    Johnson, Kimberly J.
    Gutmann, David H.
    [J]. JOURNAL OF PAIN RESEARCH, 2019, 12 : 2555 - 2561
  • [10] Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life
    Cohen, J. S.
    Levy, H. P.
    Sloan, J.
    Dariotis, J.
    Biesecker, B. B.
    [J]. CLINICAL GENETICS, 2015, 88 (05) : 425 - 430